Class Central is learner-supported. When you buy through links on our site, we may earn an affiliate commission.

The University of Chicago

Early-Stage TNBC: What are the Roles of PARPIs?

The University of Chicago via Independent

Overview

Explore the latest groundbreaking treatment approaches for early-stage triple-negative breast cancer (TNBC) in this engaging tumor board! The multidisciplinary panel of expert faculty will dive into a case involving a patient with early TNBC and discuss the latest data and potential roles of PARP inhibitors (PARPIs) in the first CME activity offered in this TNBC series. Educational Partner: The Academy for Continued Healthcare Learning (ACHL) Medium: Online Presentation Commercial Support: Support for this activity has been provided through educational grants from Gilead Sciences Inc. Sponsored by the University of Chicago Pritzker School of Medicine and the Academy for Continued Healthcare Learning (ACHL).

Syllabus

At the conclusion of this activity, participants will be able to:

  • Discuss new targeted treatment approaches in the setting of triple-negative breast cancer;
  • Assess the current evidence and treatment recommendations with the PARPIs for TNBC;
  • Implement strategies to facilitate the use of novel therapies for TNBC in community-based settings.

Reviews

Start your review of Early-Stage TNBC: What are the Roles of PARPIs?

Never Stop Learning.

Get personalized course recommendations, track subjects and courses with reminders, and more.

Someone learning on their laptop while sitting on the floor.